Ładuje się......
Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials
BACKGROUND: High sustained virological response at 12 weeks after end of treatment (SVR12) with 12 weeks of simeprevir and sofosbuvir±ribavirin (SMV+SOF±RBV) has been demonstrated in hepatitis C virus genotype 1 (HCV-1) but is based on limited data. Therefore, we performed a meta-analysis of availab...
Zapisane w:
| Wydane w: | BMJ Open Gastroenterol |
|---|---|
| Główni autorzy: | , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
BMJ Publishing Group
2016
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4780041/ https://ncbi.nlm.nih.gov/pubmed/26966547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjgast-2015-000056 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|